Cytochrome P450 2C19 Genotype, Varies
Use
Identifying patients who may be at risk for altered metabolism of cytochrome P450 2C19 (CYP2C19) substrate medications, including clopidogrel, citalopram, and voriconazole.
Special Instructions
For cord blood specimens with an accompanying maternal blood specimen, maternal cell contamination studies (MATCC) will be performed at an additional charge. Supplemental forms and informed consent (including New York clients) are included in special instructions.
Limitations
Rare variants may be present that could lead to false-negative or false-positive results. Samples may contain donor DNA (e.g., from recent allogeneic transplantation or transfusion), which may affect accuracy. The method may not detect all variants; absence of detectable variant does not rule out other variants. Cis/trans status of multiple variants may be unknown.
New York Approved
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 57132-3
- 57132-3
- 79714-2
- 104667-1
- 69047-9
- 48767-8
- 85069-3
- 62364-5
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
Not provided
Container
Lavender top (EDTA)
Collection Instructions
Invert several times to mix blood; send in original tube; do not aliquot.
Patient Preparation
Postnatal umbilical cord whole blood acceptable; for cord blood with maternal blood specimen, contamination studies required.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |
| Refrigerated | 4 days |
| Frozen | 4 days |